LinkedInXFacebook
Subscribe
Orthopedics This Week
  • Opinions
  • |My Feed
  • |Events
  • |Company Directory
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/OFIX’s $50+ Million Purge Bill Comes Due
Legal & Regulatory and Reimbursement

OFIX’s $50+ Million Purge Bill Comes Due

October 12, 2026 7 min read Premium comments

Advertisement

OFIX’s $50+ Million Purge Bill Comes Due
Source: Pixabay and TungArt7
OrthofixKeith ValentineJohn BostjancicPatrick KeranKevin KennyCatherine Burzikseverance payemployment contractcorporate governanceboard of director liabilityArbitrator ruling

Everyone, except possibly Orthofix’s 2023 board of directors, saw this lawsuit coming a mile away. 

The bill for firing, for cause, its CEO, CFO, and chief legal officer in 2023 has come due — $24.4 million to be split between former CEO Keith Valentine, former CFO John Bostjancic (sadly, more precisely, John’s widow) and former Chief Legal Officer Patrick Keran PLUS another $28 million in legal bills.

Had Orthofix’s 2023 senior management, notably Kevin Kenny, OFIX’s President of Global Spine Sales, and its board of directors, notably chairperson Catherine Burzik, known what the decision to fire their CEO, CFO, and chief legal officer (and publicly state that the firings were “for cause”) would cost in terms of OFIX’s market value, internal disruption and an emptying of the company’s treasury — would they still have pursued the same course of action? 

The $24 Million Lawsuit Award and Settlement

The final award, dated June 24, 2026, provided $11.761 million in contract damages to Keith Valentine, all paid in cash valued as of the day before the stock drop plus more than $2 million in interest. It also awarded interest and $1,139,623.40 in attorneys' fees, costs and expenses.

Former Chief Legal Officer Keran accepted a statutory compromise offer on April 15, settling his arbitration for $4.25 million, which amount included his contract damages with interest plus attorney’s fees. Former CFO Bostjancic's April 22 agreement provided another $4.25 million and expressly denied any admission of liability or wrongdoing. His settlement also resolved his claims against former OFIX Chairperson Burzik and OFIX board member Burris.

Orthofix's second-quarter filing reported paying Valentine approximately $14.8 million for the interim award and accrued interest and paying each of the other executives $4.25 million. It accrued roughly $1.1 million for Valentine's additional fee award. Together, those disclosed amounts total approximately $24.4 million.

The executives' recovery was only part of Orthofix’s firing-related costs. Orthofix also paid approximately $10 million in 2023 to the law firm and other professionals. 

Finally, this single arbitration conclusion does not end the legal costs from the 2023 purge. Orthofix's August 2026 SEC filing described additional litigation, including claims against directors and shareholder actions. Orthofix is disputing those claims.

Former CEO Valentine’s Reaction

“I am pleased that after several years, and at great professional and personal pain and expense, we prevailed on my breach of contract claim,” said Valentine, “Orthofix repeatedly stated that its decision to terminate me, John and Pat for cause was “unanimous.” It now has been determined that the Orthofix Board was unanimously wrong and unanimously breached my employment contract.”

“John and Pat were exceptionally capable, solutions-oriented and beloved executives. After our dismissals, we collectively received hundreds of calls and messages in support from the employees, distributors and surgeons with whom we had worked for almost a decade.”

Advertisement

“I continue to believe that the Orthofix Board was wrong to prioritize personal sensitivities and animus about our private texts over the Company's long-term value.”

Valentine went further in his public comments to express his appreciation to his counsel, Kyle Bisceglie and team at Olshan, Intrinsic, where he is serving as CEO and to Pat Miles, the Boards of Alphatec, Regentis and LocateBio for their support.

John Bostjancic, prior to passing away on September 20, 2026, said, “I dutifully served as a public company CFO for nearly 10 years, working hard to drive shareholder value. I am happy to obtain this small measure of vindication, both from the arbitrator’s finding that we were improperly terminated and obtaining the full cash-value of my severance with interest and attorneys’ fees. This resolution allows me to focus on spending time with my family and friends.” 

Defamation and False-Light Claims Were Rejected

This was not, technically, a lawsuit, but it had all the intensity and drama of one. 

Arbitrator Skomal rejected Valentine's defamation and false-light claims.

He found that Valentine had not established the required falsity and concluded that the underlying record supported the substance of Orthofix's statements about inappropriate and offensive conduct. Other claims were also denied.

The two principal findings, therefore, were: Orthofix breached Valentine's severance agreement and Orthofix will pay to the fired executives the $24.4 million due to Orthofix’s (by way of its board of directors) conduct when dismissing these executives.

Why Did Orthofix Abruptly Fire, for Cause, Its CEO, CFO, and Chief Legal Officer in 2023?

Events were set in motion when Orthofix and SeaSpine agreed to merge in 2022. 

For Orthofix, SeaSpine offered the prospect of revenue acceleration: implants, biologics, surgical navigation, product development, and a complementary distribution network.

Keith Valentine was central to the leadership plan. He had led SeaSpine since 2015, following senior roles at NuVasive. He brought experience in building a spine business and relationships across a specialized industry in which surgeons, distributors, and engineers know the people behind the products.

Advertisement

Bostjancic brought extensive finance and operating experience. His background included Merck, PricewaterhouseCoopers and numerous senior positions at Integra LifeSciences before becoming SeaSpine's CFO and later its chief operating and financial officer. He had served as acting CFO of the SeaSpine business within Integra before the spin-off. Keran, SeaSpine's general counsel, became the combined company's chief legal officer.

The all-stock transaction, announced in October 2022, was completed on January 5, 2023.

Two hundred and fifty days later, Valentine, Bostjancic and Keran would be fired “for cause.”

The Arbitrator’s Statement of Fact

According to the arbitrator’s statement of fact, Kevin Kenny, Orthofix’s President of Global Spine sales, triggered the chain of events that eventually led to the three firings.

On June 23, 2023, he filed a formal, confidential internal complaint alleging wine at work dinners, excessive spending, and creating an inappropriate “tone from top.” He also alleged inappropriate conduct, intoxication and inappropriate sexual relations in the workplace.

That prompted a board investigation led by Chairperson Cathy Burzik and board member Wayne Burris.

Importantly, Kenny did not provide specifics for many of his allegations, just a general statements many of which repeated workplace innuendo and hearsay.

Latham & Watkins conducted the investigation. A special committee chaired by Wayne Burris included directors from both legacy companies. Hogan Lovells advised on process and governance.

This author could find no corroborating evidence for Kenny’s allegations in legal documents or the arbitrator’s ruling. Yet, millions of dollars and teams of Latham & Watkins attorneys interviewed employees and sifted through tens of thousands of documents trying to find such evidence. 

What they eventually unearthed was a handful of text messages — specifically 23 private text messages, circulated only among the three men, and which largely predated their employment with Orthofix or their June 2023 severance agreements.

The Text Messages That Pushed OFIX Off the Cliff

Advertisement

Some of the text messages were more than ugly. They discussed employees, directors, advisers and other people encountered through work and used sexually explicit and degrading language.

The shock and disgust among the board members was understandable. 

Relying on their two law firms, the directors discussed the evidence and options. The arbitrator did not describe the board’s discussions in his ruling, but those discussions appeared only a week or two after the text messages were found.

When it came, the board’s decision was to fire Valentine, Bostjancic, and Keran was unanimous.

Why the rush?

In retrospect, it’s fair to wonder, did anyone on OFIX’s board say, in the heat of those moments: “What’s the rush? Why would we want to make these offensive and still private texts public? We don’t want litigation; we don’t want internal disruption. We can certainly hold these men accountable. But above all, Orthofix and its many stakeholders must not pay the price. We’re not going to engage in mutually assured destruction.”

Board Chair Catherine Burzik became interim CEO. Geoffrey Gillespie became interim CFO, and Puja Leekha became interim chief legal officer. Valentine was asked to resign from the board. Planned investor events were canceled or postponed.

What was the “Cause” ?

In the September 12th public announcement of the firings, there was no explanation of “cause.”  

In an industry that had known and admired Valentine for well over a quarter century, the combination of abrupt removal and limited explanation left all who read the news to speculate — did the men embezzle funds? Did they mislead Orthofix in the merger? 

It was impossible for those who knew these men to imagine that anything they would do could ever justify this kind of treatment.

Reaction, Arbitrator’s Findings, No Vindication

Advertisement

The shock and blow back to Orthofix and each of the fired executives was fast and powerful. 

Orthofix’s stock fell 30.2% representing $206 million in lost market value.

Within three months of the firings, both Board Chair Catherine Burzik and Global Spine Sales President Kevin Kenny left Orthofix. 

Orthofix was found not guilty of breaking the law. The arbitrator did find that Orthofix had breached Valentine’s contract — which was identical to the contracts held by Bostjancic and Keran. 

But Valentine's substantial financial victory did not vindicate the messages that helped trigger his dismissal nor vindicate the damage done to his career by Orthofix’s actions.

Lessons

When an acquisition depends as heavily as this one did on a particular management team, the board needs a credible continuity plan if that team must be replaced. Surgeons still require support, distributors need answers, and employees need priorities while executives and lawyers manage, adroitly one hopes, such transitions.

Looking back, which assumptions proved wrong? Were contracts sufficiently clear? Was the risk of damages and interest understood? Did the legal professionals advising the board properly apprise them of the legal risks to the company their actions would have? Did the company learn something that should change future investigations, agreements, or decision processes?

One piece of information not generally known is that Keith Valentine, as Orthofix’s CEO, proposed an alternative path which was to sever Keran, Bostjancic and his own employment voluntarily and in stages so as to ensure a less disruptive transition. In retrospect, that could have limited stakeholder uncertainty and maintain, as much as possible, shareholder value.

For directors elsewhere, this episode offers a practical warning: protecting corporate standards requires wisdom, balance, and a fulsome understanding of the cost of making decisions under duress and high emotion. 

Author

RY
Robin Young

Why This Matters

Two Perspectives

MBA Lens: Economic and industry impact

Orthofix incurred over $50 million in costs from the "for cause" termination of its CEO, CFO, and CLO, including $24.4 million in arbitration awards and settlements, plus $28 million in legal fees. This decision, following the SeaSpine merger, significantly impacted the company's market value, treasury, and internal operations, highlighting critical corporate governance and strategic execution failures by the 2023 board.

  • The substantial financial outlay for severance and legal expenses underscores the high cost of disputed executive terminations and potential board liability.
  • The incident disrupted post-merger integration and leadership stability, raising questions about the board's due diligence and risk assessment in strategic personnel decisions.

PhD Lens: Clinical and outcomes impact

The Orthofix executive firings stemmed from allegations of inappropriate workplace conduct and private text messages, not issues related to product efficacy, safety, or clinical outcomes. An arbitrator found Orthofix breached employment contracts, awarding $24.4 million, but rejected defamation claims, noting the underlying record supported the substance of the company's statements regarding conduct. The investigation did not uncover scientific or clinical misconduct.

  • The basis for termination involved personal conduct and communication, unrelated to biomedical research, materials science, or clinical trial integrity.
  • Arbitration focused on contractual breaches and workplace behavior, without addressing any scientific or medical product performance issues.
React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

Orthopedics This Week’s mission is to connect the orthopedic community with the people, ideas, and innovations shaping the future of musculoskeletal care.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Opinions
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, opinions, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy